What the bar is in platinum resistant ovarian cancer.
Since it looks like the we'd most likely get data from the PD-1 combo trial first, I did a short search to see at what recent results there have been for ovarian cancer. Overall, there does not seem to have been much activity, but in 2014, Avastin was approved for platinum resistant ovarian cancer. If you know of any others, please share.
You can look on pubmed for the Aurelia trial for Avastin, but here is a summary:
"The PFS hazard ratio (HR) after PFS events in 301 of 361 patients was 0.48 (95% CI, 0.38 to 0.60; unstratified log-rank P < .001). Median PFS was 3.4 months with chemotherapy alone versus 6.7 months with bevacizumab-containing therapy. RECIST ORR was 11.8% versus 27.3%, respectively (P = .001). The OS HR was 0.85 (95% CI, 0.66 to 1.08; P < .174; median OS, 13.3 v 16.6 months, respectively). Grade ≥ 2 hypertension and proteinuria were more common with bevacizumab. GI perforation occurred in 2.2% of bevacizumab-treated patients.
Conclusion Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant. No new safety signals were observed."
It got approved and there does not seem to be an OS benefit. If TPIV200 can show survival benefit, then this would be a huge boost for patients.
Also, immunotherapy takes a bit of time to kick in. In a recent talk I saw, it was mentioned that for checkpoint inhibitors, the early part of the survival curve looks similar to the control arm. Hopefully a combo can help patients see benefit sooner.
